As 2024 gets rolling, clarity around the investment market’s rebound — one of the key questions in the life sciences industry this year — is already forming.
In a recent PharmaVoice newsletter reader poll, 67% of respondents said they believe the biotech market will recover from a yearslong slump of lowered investments and rampant layoffs across the industry. By many measures, such as recent M&A activity, biotech is indeed on the upswing.
Plenty of other questions are still hanging over the year ahead in life sciences, though. To offer some clarity and predictions on how 2024 will shape up, PharmaVoice tapped into its community of thought leaders and readers for insights.
Here’s a look at some of the key trends on the horizon in pharma this year.